OZOuidad Zehou

Ouidad Zehou

*This is an algorithmically generated author record based on publicly available information.

Ouidad Zehou has a total of 192 co-authors. Here are the top co-authors by number of shared publications:

  • Caroline Gaudy-Marqueste

    Dermatology and Skin Cancer Department Aix Marseille University Marseille Cedex 07 France

    4 shared publications
  • Céleste Lebbé

    Université Paris Cite, AP-HP Dermato-oncology and CIC, Cancer Institute APHP.nord Paris cité, INSERM U1342—Equipe—CNRS EMR8000, Saint Louis Hospital, Paris, France

    4 shared publications
  • Eve Maubec

    Department of Dermatology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Paris Nord University, Bobigny, France; INSERM UMR 1124, Université Paris Cité, Paris, France

    4 shared publications
  • Pierre Wolkenstein

    Affiliations Department of Dermatology, Henri Mondor University Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), Referral center for Neurofibromatosis (CERENEF), Creteil, France, Inserm, Clinical Investigation Center 1430, Henri Mondor University Hospital, AP-HP, Creteil, France, STEM REPAIR NF Team, Inserm U955, Mondor Institute for Biomedical Research (IMRB), Creteil, France, Université Paris Est Créteil (UPEC), Créteil, France

    4 shared publications
  • Arnaud Jannic

    Henri Mondor Hosp, Assistance Publ Hop Paris AP HP, Natl Referral Ctr Neurofibromatoses CERENEF, Dept Dermatol, 1 Rue Gustave Eiffel, F-94000 Creteil, France

    3 shared publications
  • Henri Montaudié

    Dermatology Department Centre Hospitalier Universitaire de Nice, Université Côte d'Azur Nice France

    3 shared publications

Latest Publications

  • Open Access

    Combined immune-related adverse events and prognosis in advanced melanoma patients treated with immune checkpoint inhibitors: VigiBase and RIC-Mel data analysis

    by Oluwafêmi Julie Marie-Josée. Hessou, Charles Dolladille, Amir Khammari, Henri Montaudié, Géraldine Jeudy, Florent Grange, Eve Maubec, Ouidad Zehou, Caroline Gaudy-Marqueste, Florence Brunet-Possenti, et al.

    IrAEs induced by Immune Checkpoints Inhibitors (ICIs) should improve survival, however the impact of multiple and severe irAEs on treatment response remains unclear. This study aimed to assess the association between irAEs pairs and response in melanoma patients. It was a retrospective observational study using the global database VigiBase, and the french RIC-Mel cohort, including melanoma patients treated with ICIs: anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab and pembrolizumab), and anti-LAG-3 (relatlimab), and who experienced at least one irAE. After identifying individual irAEs and their co-occurrences as pairs, their association with treatment response was assessed using logistic regression. We identified 31,981 ICIs-treated patients in VigiBase and 6,362 in RIC-Mel. At least one irAE occurred in 63% of VigiBase cases and 25% of RIC-Mel patients. Among patients with irAEs, 17% in VigiBase and 8% in RIC-Mel, respectively, had experienced at least two. Nearly 300 irAEs pairs were identified, most commonly involving cutaneous, gastrointestinal, endocrine, and musculoskeletal systems. Among patients with two or more irAEs, co-occurring irAEs were associated with a reduced likelihood of reported disease progression in VigiBase (significant for 8 pairs among both all cases and severe cases). In RIC-Mel, no significant associations were found, although about half of pairs with results suggested a potential likelihood of favorable treatment response, involving similar organ systems as in VigiBase. Our results suggest that the emergence of specific irAEs pairs might serve as composite markers of beneficial immune activation and therapeutic efficacy.

  • Open Access

    Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study

    by Julie Charles, Aude Belbezier, Stéphane Mouret, Brigitte Dreno, Stéphane Dalle, Céleste Lebbe, Ewa Hainaut-Wierzbicka, Andreea Stefan, Julie de Quatrebarbes, Olivier Dereure, et al.

    Background: Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC. To test this hypothesis, we conducted a Phase II, non‐randomized, open trial investigating lanreotide in MCC patients with advanced disease ( ClinicalTrials.gov identifier: NCT02351128). Methods: Patients with Stage IIIB‐IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity. The primary endpoint was disease control rate (DCR) (defined as the proportion of patients with complete response, partial response, and stable disease) at 3 months. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), somatostatin receptor (SSTR) tumor expression, and treatment safety. Results: Between April, 2015, and November, 2016, 35 patients received lanreotide, with 12 evaluable at 3 months. The DCR at 3 months was 33.3% (4) among evaluable patients (all with stable disease) and 11.4% for the full cohort. Statistical analyses showed no significant difference from the expected 20% response rate ( p = 0.205 for intention‐to‐treat; p = 0.939 for per‐protocol). Kaplan–Meier analysis revealed median OS and PFS of 3.1 months (95% CI, 2–5.5) and 3.5 months (95% CI, 2.3–5.5), respectively. SSTR tumor expression did not correlate with treatment response. Conclusion: Although limited by its implementation before the era of immunotherapy, this non‐randomized study shows the limited effectiveness of lanreotide as monotherapy in treating patients with advanced MCC. Trial Registration: Identifier: NCT02351128

  • Open Access

    Real-world management and outcomes of patients with unresectable cutaneous squamous cell carcinoma treated with systemic therapy: Insights from the French CAREPI Study Group

    by Sofia Tzoumpa, Maxime Leroy, Isabelle Scheer, Gaëlle Quéreux, Géraldine Jeudy, O. Zehou, Marie Beylot-Barry, Caroline Gaudy-Marqueste, Henri Montaudié, Mona Amini-Adle, et al.

    Background:Although anti-programmed-death-(ligand)-1 (anti-PD-(L)1) therapies are approved for advanced cutaneous squamous cell carcinoma (aCSCC), real-world evidence on treatment patterns, outcomes and prognostic factors remains limited.Objectives:To assess the real-world efficacy and safety of aCSCC therapies according to treatment type (anti-PD-(L)1 vs non-anti-PD-(L)1) and identify predictive factors of survival.Methods:This retrospective-prospective multicenter French study included patients with unresectable locally advanced or metastatic CSCC receiving first-line systemic therapy. Survival outcomes were assessed using the Kaplan-Meier method and Cox models.Results:Among 662 patients (median age, 82 years), 74% were men, 77% had head and neck (HN) primary tumours, 30% had performance status (PS) ≥2 and 25% were immunocompromised. Most received first line anti-PD-(L)1 therapy (n=584) whereas 78 received anti-EGFR therapy and/or chemotherapy; the latter group included more transplant recipients (38% vs 3%). Overall response rates were similar between treatment groups (50.5% vs 41.0%, p=0.209) while median duration of response was longer with PD-(L)1 (23 vs. 9 months, p=0.046). Overall, median progression-free survival (PFS) and overall survival (OS) were 11 and 24 months. Non-HN primary tumors, PS≥2, and immunocompromised status independently predicted poorer PFS/OS. Anti-PD-(L)1 therapy improved PFS, while age≥82years predicted worse OS. Only 59% of patients with progression received second-line systemic therapy. Severe treatment-related adverse events were comparable between treatment groups (10.1% vs. 14.1%, p=0.300).Conclusions:Although anti-PD-(L)1 therapy provides more durable responses and longer PFS than alternative treatments in aCSCC, our findings identify distinct patient subgroups with persistently poor outcomes that require improved therapeutic strategies and clinical management.

  • Open Access

    Prognostic classification of skin adnexal carcinomas: results from a prospective study of 980 patients in the French CARADERM network

    by Robin Zagala, Stéphane Dalle, Brigitte Balme, Emilie Gerard, Marie-Laure Jullie, Marie Crinquette, Philippe Saiag, Benjamin Bonsang, Cecile Pages, Laurence Lamant, et al.

    BackgroundSkin adnexal carcinomas (SAC) comprise a rare and heterogeneous group of malignancies with variable prognosis. Due to the lack of established guidelines for initial staging and follow-up, this study aimed to analyse recurrence risks across SAC subtypes to provide a framework for subtype-specific treatments options and follow-up.MethodsThis nationwide multicentre prospective study, using the CARADERM database, included patients diagnosed with primary and localised SAC between March 2014 and March 2024. Subtypes with fewer than 15 cases were excluded from the prognostic analysis. Recurrence was classified as local, regional, or distant, with a three-year follow-up endpoint. Recurrence risks were stratified as low (<5%), moderate (5–15%), or high (≥15%) for local and regional recurrences and as low (0%), moderate (0–5%), or high (≥5%) for distant recurrences.ResultsAmong 980 eligible patients, distinct recurrence patterns were identified across subtypes. Subtypes with high global recurrence risk included adnexal carcinomas NOS, apocrine carcinomas, mucinous adenocarcinomas and squamoid eccrine ductal carcinomas, with three-year cumulative recurrence rate of 29.3%. In contrast, low-risk subtypes such as low-grade trichoblastic carcinomas, pilomatrical carcinomas, proliferating trichilemmal tumor and digital papillary adenocarcinomas, exhibited a global recurrence rate of 1.5%. Local, regional, and distant recurrence risks varied among subtypes, emphasising their heterogeneous clinical behavior.ConclusionThis is the first prospective multicentre study to define recurrence-based risk stratification across SAC subtypes. These findings underscore the need for subtype-specific strategies and provide the foundation for evidence-based staging and follow-up algorithms for rare skin carcinomas.

  • Genetic landscape of non‐ UV ‐induced cutaneous squamous cell carcinomas

    by Carmen Al Youssef, Mansour Alkobtawi, Rémi Safi, Johan Chanal, Pierre Sohier, Stéphanie Leclerc‐Mercier, Ouidad Zehou, Nicolas Ortonne, Philippe Moguelet, Patricia Senet, et al.

    Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is most often caused by cumulative UV exposure. However, cSCC may also arise independently of UV exposure, on sites of sustained skin damage like chronic ulcers, scars, Recessive Dystrophic Epidermolysis Bullosa (RDEB), and inflammatory skin diseases such as hidradenitis suppurativa (HS). Little is known about non‐UV‐induced skin carcinomas. We aimed to describe the clinical, pathological, and genetic features, of non‐UV‐induced cSCC. We collected clinical and pathologic data corresponding to 31 patients with non‐UV‐induced cSCC, including 5 cSCC on HS, 4 on chronic leg ulcers and 8 on RDEB. DNA was extracted from FFPE samples and analysed using a NGS assay targeting 523 cancer genes. A comparison was performed with published genetic data obtained in non‐UV‐induced and UV‐induced cSCC. We found that the Tumour Mutational Burden (TMB) of non‐UV‐induced cSCC was 6‐times lower than the published TMB of UV‐induced cSCC. The predominant mutational signature was a clock‐wise signature. By comparing the frequency of driver mutations, we found TP53 and NOTCH1 to be significantly less frequently mutated than in UV‐mutated cSCC. Interestingly, KMT2B (a histone methyl transferase) was mutated in 11/31 non‐UV‐induced cSCC and this proportion was significantly higher than in UV‐mutated cSCC. These mutations were high impact loss‐of‐function mutations. We found that knocking down KMT2B expression using siRNA did not affect cell proliferation of SCC‐13 and A‐431 cell lines, however, it significantly increased cell migration in vitro . Taken together, this study provides a comprehensive description of non‐UV‐induced cSCC and identifies that KMT2B is mutated and involved in non‐UV‐induced cSCC carcinogenesis. © 2025 The Pathological Society of Great Britain and Ireland.

  • Open Access

    Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network

    by Robin Zagala, Stephane Dalle, Marie Beylot‐Barry, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, Ouidad Zehou, Mona Amini‐Adle, Jean‐Jacques Grob, et al.

    Background: Cutaneous adnexal carcinomas are a heterogeneous group of rare neoplasms. Surgical excision is the first‐line treatment in localized stage. The use and effectiveness of radiotherapy have not been thoroughly evaluated in these neoplasms.Objectives: The present work analyses prognostic factors on outcomes in skin adnexal carcinomas, based on data from the CARADERM (CAncers RAres DERMatologiques) database.Methods: Data were collected retrospectively including demographic data, tumour types and therapeutic characteristics of all patients included in the CARADERM database, with at least one informative follow‐up visit. Analyses were performed on three populations: patients with complete resection of the primary tumour (ADJ/primary population), patients achieving complete remission after complete resection of a recurrent tumour (ADJ/recurrent population) and patients with unresectable locally advanced or metastatic tumours (ADV/MET population). Overall and recurrence/progression‐free survivals at 3‐year were analysed using Cox regression models.Results: Radiotherapy did not affect overall survival (OS) in the ADJ/primary population. Adjusted recurrence‐free survival (RFS) was significantly lower in the radiotherapy group in ADJ/primary group. Older patients had significantly poorer OS and RFS. Tumour size and immunosuppression were significantly associated with poorer RFS only. Radiotherapy had no effect on OS and RFS in the ADJ/recurrent population. Age was the only factor associated with a poorer OS. Radiotherapy was significantly associated with longer progression‐free survival (PFS) in age‐sex adjusted analysis in the ADV/MET population, without effect on OS.Conclusions: Our study shows that age, tumour size and immunosuppression are significantly associated with survival in localized adnexal carcinomas. Radiotherapy may improve PFS in the ADV/MET population but not in localized and recurrent carcinomas after complete excision.


  • Whole-Body Positron Emission Tomography with 18F-Fluorodeoxyglucose/Magnetic Resonance Imaging as a Screening Tool for the Detection of Malignant Transformation in Individuals with Neurofibromatosis Type 1

    by Laura Fertitta, Arnaud Jannic, Ouidad Zehou, Christina Bergqvist, Salah Ferkal, Sabine Moryousef, Lionel Lerman, Sébastien Mulé, Alain Luciani, Blanche Bapst, et al.


  • Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicentre retrospective study of 110 patients

    by Chloé Grolleau, Anouk Walter-Petrich, Nicolas Dupin, Johan Chanal, Ouidad Zehou, Claire Montlahuc, Barouyr Baroudjian, Laetitia Da Meda, Matthieu Resche-Rigon, Laurence Le Cleach, et al.

    Although systemic treatments are warranted in aggressive forms of classic and endemic Kaposi sarcomas (KS), therapeutic guidelines are lacking for those nonimmunodeficient subtypes. In this retrospective multicentre study, we showed that paclitaxel, liposomal doxorubicin and low-dose interferon had good overall response rates for nonimmunodeficient KS with acceptable tolerance profiles. In addition, we highlighted the aggressiveness of endemic KS compared with classic KS with a higher risk of dissemination and response depletion as progression proceeded.


  • In-Hospital Clinical Features, Morbidity, and Mortality of Patients with Neurofibromatosis 1 in France: A Nationwide, Population-Based Retrospective Cohort Study

    by Emmanuelle Diaz, Christina Bergqvist, Bastien Peiffer, Laura Fertitta, Arnaud Jannic, Salah Ferkal, Ouidad Zehou, François Hemery, Emilie Sbidian, Pierre Wolkenstein


  • A process modelling approach to assess the impact of teledermatology deployment onto the skin tumor care pathway

    by Tu Anh Duong, Guillaume Lamé, Ouidad Zehou, Charbel Skayem, Patricia Monnet, Mohammed El Khemiri, Sonia Boudjemil, Gaëlle Hirsch, Pierre Wolkenstein, Marija Jankovic